City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Marianna Koczywas, MD  
Search results:  10  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-10 Trials Jump to page:

COH Protocol Number: 17056 ClinicalTrials.gov Number: NCT02595944

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

COH Protocol Number: 16195 ClinicalTrials.gov Number: NCT02496663

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-77, NCI#9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

COH Protocol Number: 16177 ClinicalTrials.gov Number: NCT02860286

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function

COH Protocol Number: 16069 ClinicalTrials.gov Number: NCT02382406

Principal Investigator: Marianna Koczywas, MD
Sponsor: Institutional

Title:  Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15453 ClinicalTrials.gov Number: NCT02823990

Principal Investigator: Marianna Koczywas, MD
Sponsor: Institutional

Title:  Phase II Trial of TG4010 Plus Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed After One Line of Systemic Therapy

COH Protocol Number: 15236 ClinicalTrials.gov Number: NCT02535312

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-76, NCI#9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

COH Protocol Number: 15147 ClinicalTrials.gov Number: NCT02194738

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

COH Protocol Number: 15146 ClinicalTrials.gov Number: NCT02193282

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non- Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 15145 ClinicalTrials.gov Number: NCT02201992

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN E4512:ALCHEMIST E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

COH Protocol Number: 14203 ClinicalTrials.gov Number: NCT02154490

Principal Investigator: Marianna Koczywas, MD
Sponsor: Cooperative Group

Title:  SWOG S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP)

 
Results per page: 25 50 100 All 1-10 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.